CD19 and neoplasm: Unlike the treatment of hematologic malignancies where the CD19-CAR T cells recognize the CD19+ tumor cells in the blood, CAR T cells must travel from the blood into solid tumor sites and infiltrate the stromal elements of the solid tumors.